To assess the effects of oral substitution treatment for opioid-dependent injecting drug users on HIV risk behaviors and infections.
T his paper presents the main findings of a systematic (Cochrane) review. The full review 1 should be consulted for detail of the methods and results. The goal of this review was to assess the effectiveness of oral substitution treatment for opioid-dependent injecting drug users (IDU) in preventing the spread of HIV.
In the United States, 22% of AIDS cases diagnosed in 2003 were attributed to injection drug use. 2 
Data Sources
Multiple electronic databases were searched from their date of commencement (the latest was 1985) to July 2003 using a strategy addressing opioid dependence, HIV transmission and methadone, and other substitution treatment agents.
Eligible studies included opioid-dependent injecting drug users; involved the oral administration of opioid agonists for substitution treatment; and considered behaviors with a high risk for HIV transmission, or the incidence of HIV infection.
Review Methods
The data from the studies varied in a number of aspects, including the interval between baseline and follow-up interviews; the proportion of participants injecting at baseline; the reporting period for assessment of HIV risk behaviors; and the means of reporting frequency data. This variability reduced the validity of any calculated combined effect. Consequently, this review was limited to a descriptive summary of studies of varying methodologies, which considers the consistency in outcomes reported by the individual studies without metaanalysis to quantify overall effect size.
Primary outcome measures were behaviors with a high risk of transmission of HIV, including injecting drug use, sharing of injecting equipment, unprotected sex, multiple sexual partners, and providing sex in exchange for money or drugs. The incidence of HIV was also assessed.
RESULTS

Description of Included Studies
Twenty-eight studies involving 7,900 participants were included in the review. In all 28 studies, methadone was used for substitution treatment. Only 2 studies 3,4 were randomized controlled trials of oral substitution treatment. The studies reported 4 types of data: HIV risk behavior at baseline prior to treatment entry, and at follow-up, after a period of methadone treatment (18 studies); HIV risk behavior for participants receiving methadone treatment at the time of assessment compared with participants receiving no or limited methadone treatment (4 studies); HIV risk behaviour in cohorts of drug users either continuing in or ceasing methadone treatment (3 studies); and exposure to methadone treatment for cohorts who HIV seroconverted or remained HIV seronegative over a defined period (4 studies). of drug-related HIV risk behavior before and after a period of methadone treatment found significant decreases. In the fourth study 4 there was a nonsignificant reduction in the mean score between intake and 6-month follow-up. Another study 23 reported significantly lower drug risk scores for a cohort of IDU in methadone maintenance with cohorts not in treatment at the time of assessment.
Effect of Methadone Treatment on Sex-Related Risk
In 3 5,6,17 of 4 studies that reported data on the proportion of participants reporting multiple sex partners or exchanges of sex for drugs or money, significantly fewer participants reported these behaviors following methadone treatment, compared with baseline. Relatively few participants in the fourth study 8 reported these behaviors either before (5 of 69) or after (7 of 69) methadone treatment. Two studies provided data on exchange of sex for drugs or money for cohorts of drug users receiving or not receiving methadone treatment at the time of interview. One study 16 found that significantly fewer of the cohort in methadone treatment reported exchanges; the other study 15 reported a significantly lower frequency of exchanges for the cohort in methadone treatment. Data on exposure to unprotected sex was reported in different ways. A statistic that could be extracted from most studies was the use of condoms on half or less of occasions. Hence this was used as the definition of exposure to unprotected sex. found that fewer participants reported unprotected sex at follow-up, and in the other 8 most participants reported unprotected sex (84% at baseline, 88% at follow-up). Two studies 16, 19 comparing cohorts of IDU in or out of methadone treatment found no significant difference in condom use. A third study 15 reported a higher frequency of condom use in the 30 days prior to interview for a cohort not in methadone treatment, compared with those currently in methadone treatment (standardized mean difference À 0.28, 95% CI À 0.55, 0.00). Two studies 21, 22 reported scores of sex-related risk from scales of HIV risk behaviors found a significant reduction in the score from baseline to follow-up after 6 months of substitution treatment. A third study 4 reported a nonstatistically significant reduction. One study 23 found no difference in sex-related risk scores for IDU currently in methadone maintenance treatment, compared with those previously in, or with no prior history of methadone maintenance.
Effect of Methadone Treatment on Seroconversion
Metzger et al. 16 found that over a period of 18 months, the odds of seroconversion among an untreated group, compared with a group in methadone treatment, were 7.63 (CI 1.99, 29.27, Po.01).
Moss et al. 24 reported that 11 of 145 (7.6%) with less than 12 lifetime months in methadone maintenance seroconverted, compared with 11 of 536 (2.1%) with 12 or more lifetime months of methadone maintenance (P =.002). Williams et al. 25 reported a seroconversion rate of 0.7 per 100 person years for those in continuous methadone treatment (mean 29 months), compared with 4.3 per 100 person years for those with interrupted treatment (over a mean 53 months). Serpelloni et al. 26 found that the risk of HIV infection increased 1.5 times for every 3 months out of methadone treatment in the 12 months prior to seroconversion.
DISCUSSION
The studies identified in this review, whether controlled trials or other types of study, provide evidence that methadone treatment in opioid-dependent IDU is associated with significant reductions in HIV risk behaviors as well as rates of HIV seroconversion.
The studies consistently revealed a decrease in the proportion of participants reporting injecting use, the frequency of injection, the sharing of injecting equipment, and drug-related HIV risk scores.
The data suggest that methadone treatment is associated with a lower likelihood of multiple sex partners or exchanges of sex for drugs or money but no change, or only small decreases, in unprotected sex. This indicates an effect on behaviors that are probably directly related to obtaining drugs, but not on behaviors that are influenced by other factors, such as capacity and willingness to negotiate the use of condoms.
Importantly, the studies of seroconversion rates are consistent in indicating lower rates of seroconversion associated with methadone treatment. This suggests that reductions in risk behavior do translate into actual reductions in cases of HIV infection.
It is unclear to what extent continued injecting behavior during methadone treatment is related to the use of nonopioid drugs. Assessing the extent of reduction of HIV risk behavior associated with methadone treatment of injecting opioid users will require further knowledge of the drugs being injected by those who continue injecting after entry into methadone treatment.
One recent study 27 reported a significant reduction in HIV risk associated with buprenorphine maintenance treatment, but in the absence of other studies, it is currently not possible to compare methadone with other forms of substitution treatment in terms of capacity to reduce HIV risk behavior. Similarly, different types of psychosocial interventions should be compared with methadone treatment on capacity to reduce HIV risk behavior. Most controlled trials comparing methadone with other substitution pharmacotherapies rely on urine screening and retention in treatment as primary outcome measures. Including an assessment of HIV risk behavior as an outcome measure in controlled trials would add a further important dimension to the assessment of effectiveness of substitution therapies.
The studies identified in this review add to the strong evidence of effectiveness of methadone treatment on drug use, and treatment retention outcomes shown by other systematic reviews while providing important data on the efficacy of methadone treatment in decreasing HIV risk behaviors. 28, 29 The provision of methadone treatment for injecting drug users significantly reduces the risk of transmission of HIV and should be provided as a component of a strategic approach to the prevention and control of HIV infection.
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